{"entity":{"id":"atigotatug","kind":"drug","name":"Atigotatug","aka":["BMS-986489 (Atigotatug"],"tldr":"Atigotatug is an experimental monoclonal antibody from Bristol-Myers Squibb in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.","summary":"Atigotatug (BMS-986489) is a monoclonal antibody developed by Bristol-Myers Squibb. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: Atigotatug is an anti-fucosyl-GM1 antibody supplied as a fixed-dose combination with the PD-1 inhibitor nivolumab. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06646276 (A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)), in non-small-cell lung cancer. The largest, NCT06646276, plans to enrol 530 participants with primary completion expected 2028-04-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Atigotatug","url":"https://clinicaltrials.gov/search?intr=Atigotatug"},{"label":"Sponsor pipeline page","url":"https://www.bms.com/researchers-and-partners/in-the-pipeline.html"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06646276"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"BMS-986489","modality":"monoclonal antibody","mechanism":"Atigotatug is an anti-fucosyl-GM1 antibody supplied as a fixed-dose combination with the PD-1 inhibitor nivolumab.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/atigotatug/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"trial":[{"id":"nct06646276","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)","route":"/trials/nct06646276/"}]}}